Turnstone Biologics Corp. (NASDAQ:TSBX) Shares Bought by Zimmer Partners LP

Zimmer Partners LP grew its position in Turnstone Biologics Corp. (NASDAQ:TSBX) by 271.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 179,026 shares of the company’s stock after purchasing an additional 130,826 shares during the quarter. Zimmer Partners LP’s holdings in Turnstone Biologics were worth $469,000 at the end of the most recent reporting period.

Separately, Citigroup Inc. purchased a new stake in Turnstone Biologics during the third quarter worth approximately $30,000. Hedge funds and other institutional investors own 52.51% of the company’s stock.

Turnstone Biologics Stock Up 2.5 %

TSBX stock traded up $0.06 during midday trading on Thursday, reaching $2.44. 40,935 shares of the company were exchanged, compared to its average volume of 153,781. Turnstone Biologics Corp. has a 1-year low of $1.63 and a 1-year high of $12.81. The stock’s 50-day simple moving average is $2.59 and its 200 day simple moving average is $2.81.

Turnstone Biologics (NASDAQ:TSBX) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.07). Research analysts expect that Turnstone Biologics Corp. will post -3.44 earnings per share for the current fiscal year.

About Turnstone Biologics

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.